0000899243-21-038064.txt : 20210928 0000899243-21-038064.hdr.sgml : 20210928 20210928160540 ACCESSION NUMBER: 0000899243-21-038064 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210608 FILED AS OF DATE: 20210928 DATE AS OF CHANGE: 20210928 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sorensen Benny CENTRAL INDEX KEY: 0001828516 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39615 FILM NUMBER: 211286850 MAIL ADDRESS: STREET 1: C/O CODIAK BIOSCIENCES, INC. STREET 2: 35 CAMBRIDGEPARK DRIVE, SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Codiak BioSciences, Inc. CENTRAL INDEX KEY: 0001659352 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-949-4100 MAIL ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: Codiak Biosciences, Inc. DATE OF NAME CHANGE: 20151125 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-08 0 0001659352 Codiak BioSciences, Inc. CDAK 0001828516 Sorensen Benny C/O CODIAK BIOSCIENCES, INC. 35 CAMBRIDGEPARK DRIVE, SUITE 500 CAMBRIDGE MA 02140 0 1 0 0 See Remarks Common Stock 2021-06-08 4 M 0 8533 3.29 A 8533 D Common Stock 2021-06-08 4 S 0 6893 25.5732 D 1640 D Common Stock 2021-06-08 4 S 0 1640 26.0608 D 0 D Stock Option (Right to Buy) 3.29 2021-06-08 4 M 0 8533 0.00 A 2026-10-24 Common Stock 8533 87411 D The transactions reported in this Form 4 were inadvertently reported late due to an administrative oversight related to communications of the transactions. The sales reported in this Form 4 were effected pursuant to a previously adopted Rule 10b5-1 trading plan. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $25.00 to $25.99 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $26.00 to $26.13 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. The shares underlying this option are fully vested. Former SVP, Clinical Development /s/ Yalonda Howze, by Power of Attorney for Benny Sorensen 2021-09-28